Public health activists have raised concerns about Roche’s earnings from risdiplam, a drug for spinal muscular atrophy, suggesting it could be over 100 times the development costs. Roche, however, denies these claims, highlighting expenses incurred on failed projects and continued research efforts. Despite the drug’s high cost posing challenges for many in India, Roche has implemented access programs and provides free treatment to select patients. The controversy surrounding the pricing of risdiplam underscores the ongoing debate on accessibility to life-saving medications in the country.
Roche’s Profits from Rare Disease Drug Questioned Amid Accessibility Concerns in India.
Canadian man arrested for hoax bomb threat on Bengaluru-bound flight; claimed to have explosives, shouted religious slogans.
